Resonant Capital Advisors LLC Grows Stock Holdings in Gilead Sciences, Inc. $GILD

Resonant Capital Advisors LLC grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 11.5% during the second quarter, HoldingsChannel.com reports. The fund owned 21,078 shares of the biopharmaceutical company’s stock after purchasing an additional 2,169 shares during the quarter. Resonant Capital Advisors LLC’s holdings in Gilead Sciences were worth $2,337,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Wealthfront Advisers LLC boosted its position in Gilead Sciences by 16.3% during the 2nd quarter. Wealthfront Advisers LLC now owns 248,854 shares of the biopharmaceutical company’s stock worth $27,590,000 after purchasing an additional 34,942 shares during the period. Oppenheimer Asset Management Inc. boosted its position in shares of Gilead Sciences by 3.6% in the second quarter. Oppenheimer Asset Management Inc. now owns 129,697 shares of the biopharmaceutical company’s stock worth $14,380,000 after buying an additional 4,565 shares during the period. Darden Wealth Group Inc grew its stake in shares of Gilead Sciences by 4.6% in the second quarter. Darden Wealth Group Inc now owns 4,639 shares of the biopharmaceutical company’s stock valued at $514,000 after buying an additional 206 shares in the last quarter. Brighton Jones LLC raised its holdings in shares of Gilead Sciences by 14.7% during the 2nd quarter. Brighton Jones LLC now owns 17,258 shares of the biopharmaceutical company’s stock valued at $1,913,000 after buying an additional 2,208 shares during the period. Finally, Linden Thomas Advisory Services LLC lifted its position in Gilead Sciences by 3.6% during the 2nd quarter. Linden Thomas Advisory Services LLC now owns 47,527 shares of the biopharmaceutical company’s stock worth $5,269,000 after acquiring an additional 1,630 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Citigroup lifted their price objective on shares of Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a research note on Wednesday, October 8th. BMO Capital Markets boosted their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an “outperform” rating in a report on Monday, October 20th. The Goldman Sachs Group upped their price objective on shares of Gilead Sciences from $105.00 to $108.00 and gave the company a “neutral” rating in a research report on Friday, October 17th. Needham & Company LLC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price target on the stock in a research note on Friday, July 25th. Finally, Rothschild & Co Redburn increased their price target on Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a report on Friday, September 12th. One research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and an average price target of $122.61.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $295,200.00. Following the completion of the transaction, the chief financial officer directly owned 157,055 shares of the company’s stock, valued at approximately $18,545,054.40. The trade was a 1.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $113.63, for a total transaction of $1,136,300.00. Following the sale, the chief executive officer directly owned 595,725 shares of the company’s stock, valued at approximately $67,692,231.75. This represents a 1.65% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 71,500 shares of company stock worth $8,281,540. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Stock Up 0.2%

Shares of Gilead Sciences stock opened at $120.94 on Friday. The business has a 50-day moving average price of $115.47 and a 200 day moving average price of $111.07. Gilead Sciences, Inc. has a fifty-two week low of $86.08 and a fifty-two week high of $124.61. The firm has a market cap of $150.06 billion, a P/E ratio of 24.09, a P/E/G ratio of 0.83 and a beta of 0.34. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.96 by $0.05. The company had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business’s revenue was up 1.4% on a year-over-year basis. During the same quarter last year, the firm earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s dividend payout ratio is 62.95%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.